Single-stranded phosphorothioate (PS) oligonucleotide medication have proven potential for the remedy of a number of uncommon illnesses. Nevertheless, a barrier to their widespread use is that they exhibit exercise in solely a slender vary of tissues. One technique to circumvent this constraint is to conjugate them to cationic cell-penetrating peptides (CPPs). Though there are a number of examples of morpholino and peptide nucleic acids conjugated with CPPs, there are noticeably few examples of PS oligonucleotide-CPP conjugates.
That is shocking provided that PS oligonucleotides presently characterize the most important class of accepted RNA-based medication, together with Nusinersen, that bears the two’- O -methoxyethyl (MOE) chemistry. On this work, we report a way for in-solution conjugation of cationic, hydrophobic peptides or human serum albumin to a 22-nucleotide MOE-PS oligonucleotide. Conjugates had been obtained in excessive yields and purities. Our findings pave the best way for his or her large-scale synthesis and testing in vivo .
Enteroviruses are ubiquitous mammalian pathogens that may produce gentle to life-threatening illness. We developed a multimodal, fast, correct and economical point-of-care biosensor that may detect nucleic acid sequences conserved amongst 96% of all identified enteroviruses. The biosensor harnesses the physicochemical properties of gold nanoparticles and oligonucleotides to supply colourimetric, spectroscopic and lateral flow-based identification of an unique enteroviral nucleic acid sequence (23 bases), which was recognized via in silico screening. Oligonucleotides had been designed to exhibit particular complementarity in the direction of the goal enteroviral nucleic acid to supply aggregated gold-oligonucleotide nanoconstructs.
Antisense Oligonucleotide-Primarily based Therapeutic towards Menin for Triple-Unfavorable Breast Most cancers Remedy
The tumor suppressor menin has twin capabilities, performing both as a tumor suppressor or as an oncogene/oncoprotein, relying on the oncological context. Triple-negative breast most cancers (TNBC) is characterised by the dearth of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal progress issue receptor 2 (ERBB2/HER2) and is usually a basal-like breast most cancers. TNBC is related to a dismal prognosis and an inadequate response to chemotherapies. Beforehand, menin was proven to play a proliferative position in ER-positive breast most cancers; nevertheless, the capabilities of menin in TNBC stay unknown.
Right here, we have now demonstrated that menin is expressed in numerous TNBC subtypes with the strongest expression within the TNBC Hs 578T cells. The depletion of menin by an antisense oligonucleotide (ASO) inhibits cell proliferation, enhances apoptosis in Hs 578T cells, highlighting the oncogenic capabilities of menin on this TNBC mannequin. ASO-based menin silencing additionally delays the tumor development of TNBC xenografts.
Evaluation of the menin interactome means that menin might drive TNBC tumorigenesis via the regulation of MLL/KMT2A-driven transcriptional exercise, mRNA 3′-end processing and apoptosis. The examine gives a rationale behind the usage of ASO-based remedy, focusing on menin in monotherapy or together with chemo or PARP inhibitors for menin-positive TNBC therapies.
Synthesis of Oligonucleotides Containing trans Mitomycin C DNA Adducts at N6 of Adenine and N2 of Guanine
Mitomycin C, (MC), an antitumor drug, is a DNA alkylating agent presently used within the clinics. Inert in its native type, MC is diminished to reactive mitosenes which endure nucleophilic assault by guanine or adenine bases in DNA to type monoadducts in addition to interstrand crosslinks (ICLs). Though ICLs are thought-about essentially the most cytotoxic lesions, the position of every particular person adduct within the drug’s cytotoxicity remains to be not totally understood. Artificial routes have been developed to entry modified oligonucleotides containing dG MC-monoadducts and dG-MC-dG ICL at a single place of their base sequences to analyze the organic results of those adducts.
Nevertheless, till now, oligonucleotides containing monoadducts fashioned by MC on the adenine base had not been out there, thus stopping the examination of the position performed by these lesions within the toxicity of MC. Right here, we current a path to entry these substrates. Structural proof of the adducted oligonucleotides had been supplied by enzymatic digestion to nucleosides and excessive decision mass spectral evaluation.
Moreover, mother or father oligonucleotides containing a dG monoadduct and a dG-MC-dG ICL had been additionally produced. The soundness and bodily properties of all substrates had been in contrast through CD spectroscopy and UV melting temperature research. Lastly, digital fashions had been created to discover the conformational house and structural options of those MC-DNA complexes.
Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
Antisense oligomers (AOs) are more and more getting used to modulate RNA splicing in stay cells, each for analysis and for the event of therapeutics. Whereas the commonest supposed impact of those AOs is to induce skipping of entire exons, uncommon examples are rising of AOs that induce skipping of solely a part of an exon, via activation of an inside cryptic splice website. On this report, we examined seven AO-induced cryptic splice websites in six genes.
C1orf148 Protein Vector (Human) (pPM-C-His) |
|||
| PV066148 | ABM | 500 ng | Ask for price |
C1orf148 3'UTR Luciferase Stable Cell Line |
|||
| TU002091 | ABM | 1.0 ml | EUR 1672.8 |
C1orf148 Protein Vector (Human) (pPB-His-MBP) |
|||
| PV329902 | ABM | 500 ng | Ask for price |
C1orf148 Protein Vector (Human) (pPB-His-GST) |
|||
| PV329903 | ABM | 500 ng | Ask for price |
C1orf148 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0213902 | ABM | 1.0 ug DNA | EUR 184.8 |
C1orf148 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0213903 | ABM | 1.0 ug DNA | EUR 184.8 |
C1orf148 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0213904 | ABM | 1.0 ug DNA | EUR 184.8 |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720047 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720051 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV720052 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Protein Vector (Human) (pPM-N-D-C-HA) |
|||
| PV329904 | ABM | 500 ng | Ask for price |
C1orf148 Protein Vector (Human) (pPM-N-D-C-His) |
|||
| PV329905 | ABM | 500 ng | Ask for price |
C1orf148 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0213905 | ABM | 3 x 1.0 ug | EUR 451.2 |
C1orf148 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0213906 | ABM | 1.0 ug DNA | EUR 200.4 |
C1orf148 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0213907 | ABM | 1.0 ug DNA | EUR 200.4 |
C1orf148 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0213908 | ABM | 1.0 ug DNA | EUR 200.4 |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV720048 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV720049 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV720050 | ABM | 1.0 ug DNA | Ask for price |
C5orf26 (C5orf26) Antibody |
|||
| abx231120-100ug | Abbexa | 100 ug | EUR 577.2 |
C1orf123 Antibody |
|||
| 20-abx318425 | Abbexa |
|
|
C1orf103 Antibody |
|||
| abx231057-100ug | Abbexa | 100 ug | EUR 610.8 |
C1orf104 Antibody |
|||
| abx231058-100ug | Abbexa | 100 ug | EUR 577.2 |
C1orf156 Antibody |
|||
| abx231061-100ug | Abbexa | 100 ug | EUR 577.2 |
C1orf163 Antibody |
|||
| abx231062-100ug | Abbexa | 100 ug | EUR 610.8 |
C6orf130 Antibody |
|||
| abx231124-100ug | Abbexa | 100 ug | EUR 577.2 |
C6orf173 Antibody |
|||
| abx231127-100ug | Abbexa | 100 ug | EUR 577.2 |
C6orf182 Antibody |
|||
| abx231128-100ug | Abbexa | 100 ug | EUR 610.8 |
C6orf204 Antibody |
|||
| abx231129-100ug | Abbexa | 100 ug | EUR 577.2 |
C6orf211 Antibody |
|||
| abx231130-100ug | Abbexa | 100 ug | EUR 577.2 |
C9orf156 Antibody |
|||
| abx231143-100ug | Abbexa | 100 ug | EUR 577.2 |
C9orf156 Antibody |
|||
| 20-abx149327 | Abbexa |
|
|
C1orf161 Antibody |
|||
| abx146255-100ug | Abbexa | 100 ug | EUR 469.2 |
C1orf156 Antibody |
|||
| abx146257-100ug | Abbexa | 100 ug | EUR 469.2 |
C1orf111 Antibody |
|||
| abx146267-100ug | Abbexa | 100 ug | EUR 469.2 |
C6orf168 Antibody |
|||
| abx146370-100ug | Abbexa | 100 ug | EUR 469.2 |
C6orf211 Antibody |
|||
| abx146371-100ug | Abbexa | 100 ug | EUR 469.2 |
C6orf106 Antibody |
|||
| abx146379-100ug | Abbexa | 100 ug | EUR 469.2 |
C6orf118 Antibody |
|||
| abx146394-100ug | Abbexa | 100 ug | EUR 469.2 |
C6orf190 Antibody |
|||
| abx146395-100ug | Abbexa | 100 ug | EUR 469.2 |
C9orf156 Antibody |
|||
| abx146414-100ug | Abbexa | 100 ug | EUR 469.2 |
C9orf114 Antibody |
|||
| abx146415-100ug | Abbexa | 100 ug | EUR 469.2 |
C9orf102 Antibody |
|||
| abx146425-100ug | Abbexa | 100 ug | EUR 469.2 |
C1orf165 antibody |
|||
| 23150-100ul | SAB | 100ul | EUR 468 |
C6orf210 antibody |
|||
| 22198-100ul | SAB | 100ul | EUR 468 |
C9orf156 Antibody |
|||
| 44873-100ul | SAB | 100ul | EUR 302.4 |
C9orf156 Antibody |
|||
| 44873-50ul | SAB | 50ul | EUR 224.4 |
C6ORF140 antibody |
|||
| 70R-2829 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF140 antibody raised against the N terminal Of C6Orf140 |
|||
C6ORF182 antibody |
|||
| 70R-3111 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF182 antibody raised against the middle region of C6Orf182 |
|||
C1orf216 antibody |
|||
| 70R-9212 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Affinity purified rabbit polyclonal C1orf216 antibody |
|||
C6orf182 antibody |
|||
| 70R-9345 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Affinity purified rabbit polyclonal C6orf182 antibody |
|||
C6orf138 Antibody |
|||
| abx026241-400ul | Abbexa | 400 ul | EUR 627.6 |
C6orf138 Antibody |
|||
| abx026241-80l | Abbexa | 80 µl | EUR 343.2 |
C9orf156 Antibody |
|||
| abx033079-400ul | Abbexa | 400 ul | EUR 627.6 |
C9orf156 Antibody |
|||
| abx033079-80l | Abbexa | 80 µl | EUR 343.2 |
C6orf211 Antibody |
|||
| abx028716-400ul | Abbexa | 400 ul | EUR 627.6 |
C6orf211 Antibody |
|||
| abx028716-80l | Abbexa | 80 µl | EUR 343.2 |
C9orf117 Antibody |
|||
| abx122983-100ug | Abbexa | 100 ug | EUR 469.2 |
C9ORF127 antibody |
|||
| 70R-1830 | Fitzgerald | 100 ug | EUR 452.4 |
|
Description: Rabbit polyclonal C9ORF127 antibody raised against the C terminal Of C9Orf127 |
|||
C9ORF127 antibody |
|||
| 70R-1846 | Fitzgerald | 100 ug | EUR 452.4 |
|
Description: Rabbit polyclonal C9ORF127 antibody raised against the middle region of C9Orf127 |
|||
C6ORF134 antibody |
|||
| 70R-1282 | Fitzgerald | 100 ug | EUR 452.4 |
|
Description: Rabbit polyclonal C6ORF134 antibody raised against the N terminal Of C6Orf134 |
|||
C1orf165 antibody |
|||
| 70R-13073 | Fitzgerald | 100 ul | EUR 548.4 |
|
Description: Affinity purified Rabbit polyclonal C1orf165 antibody |
|||
C1orf106 antibody |
|||
| 70R-16073 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal C1orf106 antibody |
|||
C1orf116 antibody |
|||
| 70R-16074 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal C1orf116 antibody |
|||
C9orf156 antibody |
|||
| 70R-16100 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal C9orf156 antibody |
|||
C1ORF166 antibody |
|||
| 70R-5998 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF166 antibody raised against the middle region of C1Orf166 |
|||
C6ORF192 antibody |
|||
| 70R-6602 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF192 antibody raised against the N terminal Of C6Orf192 |
|||
C1ORF166 antibody |
|||
| 70R-6681 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF166 antibody raised against the middle region of C1Orf166 |
|||
C1ORF151 antibody |
|||
| 70R-6832 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF151 antibody raised against the middle region of C1Orf151 |
|||
C9ORF127 antibody |
|||
| 70R-7003 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C9ORF127 antibody raised against the N terminal Of C9Orf127 |
|||
C1ORF159 antibody |
|||
| 70R-7031 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF159 antibody raised against the C terminal Of C1Orf159 |
|||
C9ORF127 antibody |
|||
| 70R-7095 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C9ORF127 antibody raised against the C terminal Of C9Orf127 |
|||
C1ORF159 antibody |
|||
| 70R-7421 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF159 antibody raised against the middle region of C1Orf159 |
|||
C6orf113 antibody |
|||
| 70R-7909 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Affinity purified rabbit polyclonal C6orf113 antibody |
|||
C6orf113 antibody |
|||
| 70R-8412 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Affinity purified rabbit polyclonal C6orf113 antibody |
|||
C1ORF102 antibody |
|||
| 70R-3298 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF102 antibody raised against the N terminal Of C1Orf102 |
|||
C6ORF199 antibody |
|||
| 70R-3324 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF199 antibody raised against the middle region of C6Orf199 |
|||
C1ORF184 antibody |
|||
| 70R-2168 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF184 antibody raised against the C terminal Of C1Orf184 |
|||
C6ORF146 antibody |
|||
| 70R-3608 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF146 antibody raised against the middle region of C6Orf146 |
|||
C1ORF103 antibody |
|||
| 70R-3621 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF103 antibody raised against the middle region of C1Orf103 |
|||
C1ORF111 antibody |
|||
| 70R-3654 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF111 antibody raised against the N terminal Of C1Orf111 |
|||
C1ORF111 antibody |
|||
| 70R-3664 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF111 antibody raised against the middle region of C1Orf111 |
|||
C1ORF110 antibody |
|||
| 70R-3688 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF110 antibody raised against the N terminal Of C1Orf110 |
|||
C1ORF116 antibody |
|||
| 70R-3844 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF116 antibody raised against the middle region of C1Orf116 |
|||
C6ORF134 antibody |
|||
| 70R-3866 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF134 antibody raised against the middle region of C6Orf134 |
|||
C1ORF177 antibody |
|||
| 70R-3886 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF177 antibody raised against the middle region of C1Orf177 |
|||
C6orf134 antibody |
|||
| 70R-3914 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6orf134 antibody raised against the N terminal of C6orf134 |
|||
C1orf104 antibody |
|||
| 70R-3998 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1orf104 antibody raised against the middle region of C1orf104 |
|||
C1orf144 antibody |
|||
| 70R-4008 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1orf144 antibody raised against the N terminal of C1orf144 |
|||
C1orf122 antibody |
|||
| 70R-4043 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1orf122 antibody raised against the n terminal of C1orf122 |
|||
C1orf102 antibody |
|||
| 70R-4047 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1orf102 antibody raised against the N terminal of C1orf102 |
|||
C1ORF131 antibody |
|||
| 70R-4090 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF131 antibody raised against the middle region of C1Orf131 |
|||
C6ORF150 antibody |
|||
| 70R-4145 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF150 antibody raised against the middle region of C6Orf150 |
|||
C6ORF173 antibody |
|||
| 70R-4208 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF173 antibody raised against the N terminal Of C6Orf173 |
|||
C6ORF199 antibody |
|||
| 70R-4250 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF199 antibody raised against the N terminal Of C6Orf199 |
|||
C1ORF110 antibody |
|||
| 70R-4268 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF110 antibody raised against the middle region of C1Orf110 |
|||
C1ORF174 antibody |
|||
| 70R-4285 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF174 antibody raised against the middle region of C1Orf174 |
|||
C1ORF103 antibody |
|||
| 70R-4298 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF103 antibody raised against the N terminal Of C1Orf103 |
|||
C1ORF190 antibody |
|||
| 70R-4302 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF190 antibody raised against the middle region of C1Orf190 |
|||
C1ORF142 antibody |
|||
| 70R-4385 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C1ORF142 antibody raised against the middle region of C1Orf142 |
|||
C6orf154 antibody |
|||
| 70R-4433 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6orf154 antibody raised against the N terminal of C6orf154 |
|||
C6ORF154 antibody |
|||
| 70R-4442 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF154 antibody raised against the middle region of C6Orf154 |
|||
C6ORF201 antibody |
|||
| 70R-4814 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C6ORF201 antibody raised against the N terminal Of C6Orf201 |
|||
C9ORF153 antibody |
|||
| 70R-3503 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C9ORF153 antibody raised against the middle region of C9Orf153 |
|||
C9ORF138 antibody |
|||
| 70R-3538 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C9ORF138 antibody raised against the N terminal Of C9Orf138 |
|||
C9ORF117 antibody |
|||
| 70R-3540 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal C9ORF117 antibody raised against the N terminal Of C9Orf117 |
|||
C1orf112 antibody |
|||
| 31835-100ul | SAB | 100ul | EUR 302.4 |
C1orf112 antibody |
|||
| 31835-50ul | SAB | 50ul | EUR 224.4 |
C1orf175 Antibody |
|||
| 48086-100ul | SAB | 100ul | EUR 399.6 |
C1orf175 Antibody |
|||
| 48086-50ul | SAB | 50ul | EUR 286.8 |
C1orf101 Antibody |
|||
| 46367-100ul | SAB | 100ul | EUR 302.4 |
C1orf106 Antibody |
|||
| 46368-100ul | SAB | 100ul | EUR 302.4 |
C9orf116 Antibody |
|||
| 47264-100ul | SAB | 100ul | EUR 302.4 |
C9orf156 Antibody |
|||
| ABD2619 | Lifescience Market | 100 ug | EUR 525.6 |
C9orf156 Antibody |
|||
| 20-abx002463 | Abbexa |
|
|
C6orf150 Antibody |
|||
| DF12574 | Affbiotech | 200ul | EUR 420 |
C1orf163 Antibody |
|||
| DF12866 | Affbiotech | 200ul | EUR 420 |
C9orf156 Antibody |
|||
| DF2619 | Affbiotech | 200ul | EUR 420 |
C1orf114 Antibody |
|||
| DF14271 | Affbiotech | 100ul | EUR 420 |
C1orf198 Antibody |
|||
| DF15087 | Affbiotech | 100ul | EUR 420 |
C1orf105 Antibody |
|||
| 1-CSB-PA003497LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against C1orf105. Recognizes C1orf105 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
C1orf106 Antibody |
|||
| 1-CSB-PA003498GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against C1orf106. Recognizes C1orf106 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
|||
5 of those cryptic splice websites had been found via our personal experiments, and two originated from different revealed experiences. We modelled the anticipated results of AO binding on the secondary construction of every of the RNA targets, and the way these alterations would in flip have an effect on the accessibility of the RNA to splice elements. We noticed {that a} widespread predicted impact of AO binding was disruption of the exon definition sign throughout the exon’s excluded section.